Research programme: drug discovery - Dermira/Evotec SE
Latest Information Update: 28 Jun 2021
At a glance
- Originator Dermira; Evotec AG
- Developer Dermira; Evotec SE
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Pruritus
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Neurological-disorders in Germany
- 28 Jun 2021 No recent reports of development identified for research development in Neurological-disorders in USA
- 28 Jun 2021 No recent reports of development identified for research development in Pruritus in Germany